Brainsway Ltd ADR(BWAY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 58.54 | EPS (ttm) | 0.24 | Insider Own | 26.55% | Shs Outstand | 40.1M | Perf Week | -2.59% |
| Market Cap | 0.56B | Forward P/E | 27.45 | EPS next Y | 65.22% | Insider Trans | - | Shs Float | 29.5M | Perf Month | -7.14% |
| Enterprise Value | 0.50B | PEG | 0.62 | EPS next Q | 0.09 | Inst Own | 15.79% | Short Float | 0.53% | Perf Quarter | -1.7% |
| Income | 0.01B | P/S | 9.15 | EPS this Y | 70.37% | Inst Trans | 0.03% | Short Ratio | 1.36 | Perf Half Y | 1.02% |
| Sales | 0.06B | P/B | 7.05 | EPS next 5Y | 44.22% | ROA | 8.14% | Short Interest | 0.16M | Perf YTD | 46.27% |
| Book/sh | 1.97 | P/C | 8.97 | EPS past 3/5Y | - | ROE | 12.9% | 52W High | -20.06% ($17.40) | Perf Year | 74.64% |
| Cash/sh | 1.55 | P/FCF | 80.36 | Sales past 3/5Y | 24.82% 18.84% | ROIC | 11.17% | 52W Low | 94.95% ($7.14) | Perf 3Y | 688.1% |
| Dividend Est. | - | EV/EBITDA | 54.26 | EPS Y/Y TTM | 65.86% | Gross Margin | 75.32% | Volatility(W/M) | 3.43% 4.39% | Perf 5Y | 245.16% |
| Dividend TTM | - | EV/Sales | 8.25 | Sales Y/Y TTM | 31.63% | Oper. Margin | 12.47% | ATR (14) | 0.64 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.27 | EPS Q/Q | 25.36% | Profit Margin | 15.56% | RSI (14) | 40.54 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.59 | Sales Q/Q | 34.85% | SMA20 | -5.26% ($14.68) | Beta | 1.28 | Target Price | $19.27 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/12 | SMA50 | -8.06% ($15.13) | Rel Volume | 1.2 | Prev Close | $14.41 |
| Employees | 129 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | -4.5% 3.42% | SMA200 | 4.07% ($13.37) | Avg Volume(3M) | 0.11M | Price | $13.91 |
| IPO | 2019/4/17 | Option/Short | Yes/Yes | Trades | 1681 | Volume | 137,300 | Change | -3.47% |
Company
BWAY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
BrainsWay (BWAY) is a global neuromodulation medical device company that develops Deep Transcranial Magnetic Stimulation (Deep TMS), a non-invasive neurostimulation therapy. Building on FDA clearance for indications such as major depressive disorder, the company provides non-drug treatment solutions in the fields of psychiatry and neurology.
Over the past 1 year, roughly in the middle
20% below its 1-year high.
BWAY makes money exceptionally well
12.47% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +70.4% this year.
Tap to view numbers
The price looks about right
Trading at 58.5 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +688.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 15.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ASD 0.03%
IZRL 0.02%
IBRN 0.01%
EHLS 0.00%
APIE 0.00%It ranks #4 in the industry
Based on market cap of $559M.
BWAY $559M PER 58.5
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is BWAY?
BWAY belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of BWAY?
The market cap of BWAY is approximately $559M, ranking 3,137 within its sector.
What is the P/E ratio of BWAY?
BWAY has a P/E ratio of approximately 58.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BWAY?
BWAY has recorded a 52-week high of $17.40 and a low of $7.14.
